- Home
- LZ vs VIR Comparison
LZ vs VIR Comparison
Compare LZ & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- VIR
- Stock Information
- Founded
- LZ 2001
- VIR 2016
- Country
- LZ United States
- VIR United States
- Employees
- LZ N/A
- VIR N/A
- Industry
- LZ EDP Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- LZ Technology
- VIR Health Care
- Exchange
- LZ Nasdaq
- VIR Nasdaq
- Market Cap
- LZ 1.5B
- VIR 844.9M
- IPO Year
- LZ 2021
- VIR 2019
- Fundamental
- Price
- LZ $9.12
- VIR $5.41
- Analyst Decision
- LZ Hold
- VIR Strong Buy
- Analyst Count
- LZ 9
- VIR 7
- Target Price
- LZ $8.64
- VIR $32.86
- AVG Volume (30 Days)
- LZ 1.7M
- VIR 1.1M
- Earning Date
- LZ 08-06-2025
- VIR 07-31-2025
- Dividend Yield
- LZ N/A
- VIR N/A
- EPS Growth
- LZ 72.11
- VIR N/A
- EPS
- LZ 0.17
- VIR N/A
- Revenue
- LZ $690,777,000.00
- VIR $20,861,000.00
- Revenue This Year
- LZ $8.18
- VIR N/A
- Revenue Next Year
- LZ $7.23
- VIR N/A
- P/E Ratio
- LZ $53.27
- VIR N/A
- Revenue Growth
- LZ 3.25
- VIR N/A
- 52 Week Low
- LZ $5.33
- VIR $4.32
- 52 Week High
- LZ $10.60
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- LZ 58.00
- VIR 55.40
- Support Level
- LZ $8.48
- VIR $4.91
- Resistance Level
- LZ $9.14
- VIR $5.35
- Average True Range (ATR)
- LZ 0.20
- VIR 0.25
- MACD
- LZ 0.02
- VIR 0.03
- Stochastic Oscillator
- LZ 91.16
- VIR 86.21
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.